Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases

نویسندگان

  • Katsumasa Muneoka
  • Nobuhisa Kanahara
  • Shou Kimura
چکیده

OBJECTIVES The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. METHODS We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. RESULTS In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case. CONCLUSIONS We will discuss the benefits and risks of using aripiprazole for the treatment of catatonic schizophrenia and the possibility of dopamine supersensitivity psychosis.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treatment of Paroxysmal Perceptual Alteration in Catatonic Schizophrenia by Switching to Aripiprazole from Risperidone: A Case Report.

Paroxysmal perceptual alteration (PPA) is the occurrence of brief and recurrent episodes of perceptual changes. It is mainly caused by the treatment of schizophrenia patients with antipsychotics. However, diagnosis of PPA is not very prevalent among psychiatrists, partly due to underrecognition or misunderstanding that it is a worsening of psychiatric symptoms. If psychiatrists do not understan...

متن کامل

Treatment of refractory catatonic schizophrenia with low dose aripiprazole

This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extrapyramidal symptoms. The effects of ECT did not continue even for a month. However, the treatment ...

متن کامل

Determination Changes of Blood Biomarker Levels in Two Treatment status of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in Patients with Long-Term Schizophrenia

Background and objectives:  Schizophrenia is a chronic psychiatric disorder, which reduces the patient quality of life. Despite the recommendation for treating this disorder with a minimum dose of medications, antipsychotic polypharmacy has been used experimentally that cause increasing the drug interactions. Aripiprazole has low risk of metabolic has recommended as a first line a treatment fo...

متن کامل

Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia

Objectives: Schizophrenia is a severe psychiatric disorder that has profound effects on both individuals and the community. Notwithstanding the suggestion for treating schizophrenia with a minimum dose of drugs, antipsychotic polypharmacy increases the patient’s care costs and drug interactions. Aripiprazole reduces the metabolic side effects of antipsychotic polypharmacy treatment. DRD2 and HT...

متن کامل

Pm391. the Use of Amisulpride in Treatment of Patients with Residual Schizophrenia

s | 43 positive subscores, whereas no between-group differences were found. A reduction in body weight (p=0.01) and lower levels of total cholesterol (p=0.03), triglycerides (p=0.03), and prolactin (p=0.01) were noted in both groups, but no increase in extrapyramidal symptoms or prolongation of QTC. The blood concentrations of aripiprazole in all patients were in a therapeutic range at day 56, ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 5  شماره 

صفحات  -

تاریخ انتشار 2017